Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability

View Full Size 

Download

• Full Size JPEG, 1754x2481, 336.1 KB
• Small JPEG, 339x480, 24.3 KB
• Preview JPEG, 102x144, 6.0 KB
• Thumbnail JPEG, 51x72, 4.3 KB